What is Synergy Laboratories?
Synergy Laboratories operates as a high-complexity, CLIA, COLA licensed, and CAP-certified diagnostic facility. The company provides a comprehensive suite of laboratory services, including Next-Generation Sequencing, infectious disease screening, women's health diagnostics, toxicology, and advanced molecular and genetic testing. By prioritizing a 24-hour turnaround time for critical toxicology services and maintaining competitive pricing structures, Synergy Laboratories effectively addresses the dual mandate of reducing healthcare costs while simultaneously elevating the standard of patient care for providers and payers alike.
How much funding has Synergy Laboratories raised?
Synergy Laboratories has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Synergy Laboratories
PPP
Public-Private Partnership
What's next for Synergy Laboratories?
With the successful closure of this late-stage financing, Synergy Laboratories is strategically positioned to scale its diagnostic infrastructure and expand its market reach. The capital will likely be deployed to integrate further automation into its molecular testing workflows and to bolster its genetic sequencing capabilities. As the healthcare sector continues to shift toward precision medicine, the company's focus on high-accuracy, rapid-result diagnostics will be instrumental in maintaining its competitive edge. Future growth initiatives will likely center on deepening partnerships with regional healthcare networks and optimizing laboratory throughput to meet the increasing demand for specialized diagnostic services.
See full Synergy Laboratories company page
